Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 2/2011

01-02-2011 | Article

Alx3-deficient mice exhibit decreased insulin in beta cells, altered glucose homeostasis and increased apoptosis in pancreatic islets

Authors: M. Mirasierra, A. Fernández-Pérez, N. Díaz-Prieto, M. Vallejo

Published in: Diabetologia | Issue 2/2011

Login to get access

Abstract

Aims/hypothesis

Homeodomain transcription factors play an important role in the regulation of pancreatic islet function. In previous studies we determined that aristaless-like homeobox 3 (ALX3) is produced in islet cells, binds to the promoter of the insulin gene and regulates its expression. The purpose of the present study was to investigate the functional role of ALX3 in pancreatic islets and its possible involvement in the regulation of glucose homeostasis in vivo.

Methods

Alx3-knockout mice were used. Glucose and insulin tolerance tests were carried out, and serum insulin concentrations were determined. Isolated islets were used to test insulin secretion and gene expression. The pancreatic islets were also studied using both confocal and conventional microscopy.

Results

ALX3 deficiency resulted in increased blood glucose levels and impaired glucose tolerance in the presence of normal serum insulin concentrations. Insulin, glucagon and glucokinase expression were reduced in Alx3-null pancreatic islets. Reduced insulin content was reflected by decreased insulin secretion from isolated islets. Alx3-deficient islets also showed increased apoptosis, and morphometric analyses indicated that they were, on average, of smaller size than islets from control mice. ALX3 deficiency resulted in reduced beta cell mass. Finally, mature Alx3-null mice developed age-dependent insulin resistance due to impaired peripheral insulin receptor signalling.

Conclusions/interpretation

ALX3 participates in the regulation of the expression of essential genes for the function of pancreatic islets, and its deficiency alters the regulation of glucose homeostasis in vivo. We suggest that ALX3 constitutes a potential candidate to consider in the aetiopathogenesis of diabetes mellitus.
Appendix
Available only for authorised users
Literature
1.
Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ (2008) Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 118:3378–3389CrossRefPubMed
2.
Hashimoto N, Kido Y, Uchida T et al (2006) Ablation of PDK1 in pancreatic β cells induces diabetes as a result of loss of β cell mass. Nature Genet 38:589–593CrossRefPubMed
3.
Lee JW, Kim WH, Lim JH et al (2009) Mitochondrial dysfunction: glucokinase downregulation lowers interaction of glucokinase with mitochondria, resulting in apoptosis of pancreatic β-cells. Cell Signal 21:69–78CrossRefPubMed
4.
Bernardo AS, Hay CW, Docherty K (2008) Pancreatic transcription factors and their role in the birth, life and survival of the pancreatic β cell. Mol Cell Endocrinol 294:1–9CrossRefPubMed
5.
Naya FJ, Huang HP, Qiu Y et al (1997) Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/NeuroD-deficient mice. Genes Dev 11:2323–2334CrossRefPubMed
6.
Johnson JD, Ahmed NT, Luciani DS et al (2003) Increased islet apoptosis in Pdx1+/− mice. J Clin Invest 111:1147–1160PubMed
7.
Du A, Hunter CS, Murray J et al (2009) Islet-1 is required for the maturation, proliferation and survival of the endocrine pancreas. Diabetes. doi:10.​2337/​db08-0987
8.
Wobser H, Dussmann H, Kogel D et al (2002) Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not glucose-induced cell death. J Biol Chem 277:6413–6421CrossRefPubMed
9.
Malecki MT, Jhala U, Antonellis A et al (1999) Mutations in NEUROD1 are associated with the development of type 2 diabetes. Nat Genet 23:323–328CrossRefPubMed
10.
Stoffers DA, Ferrer J, Clarke WL, Habener JF (1997) Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nature Genet 17:138–141CrossRefPubMed
11.
Hani EH, Stofers DA, Chevre JC et al (1999) Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 104:41–48CrossRef
12.
Barat-Houari M, Clement K, Vatin V et al (2002) Positional candidate gene analysis of Lim homeobox gene (Isl-1) on chroosome 5q11-q13 in a French morbidly obese population suggests indication for association with type 2 diabetes. Diabetes 51:1640–1643CrossRefPubMed
13.
Shimomura H, Sanke T, Hanabusa T, Tsunoka K, Furuta H, Nanjo K (2000) Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. Diabetes 49:1597–1600CrossRefPubMed
14.
Yamagata K, Oda N, Kaisaki PJ et al (1996) Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384:455–458CrossRefPubMed
15.
Servitja JM, Pignatelli M, Maestro MA et al (2009) Hnf1α (MODY3) controls tissue-specific transcriptional programs and exerts opposed effects on cell growth in pancreatic islets and liver. Mol Cell Biol 29:2945–2959CrossRefPubMed
16.
Oliver-Krasinski JM, Kasner MT, Yang J et al (2009) The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. J Clin Invest 119:1888–1898CrossRefPubMed
17.
Servitja JM, Ferrer J (2004) Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia 47:597–613CrossRefPubMed
18.
Ten Berge D, Brouwer A, El Bahi S, Guenet JL, Robert B, Meijlink F (1998) Mouse Alx3: an aristaless-like homeobox gene expressed during embryogenesis in ectomesenchyme and lateral plate mesoderm. Dev Biol 199:11–25CrossRefPubMed
19.
Mirasierra M, Vallejo M (2006) The homeoprotein Alx3 expressed in pancreatic β-cells regulates insulin gene transcription by interacting with the basic helix-loop-helix protein E47. Mol Endocrinol 20:2876–2889CrossRefPubMed
20.
Beverdam A, Brouwer A, Reijnen M, Korving J, Meijlink F (2001) Severe nasal clefting and abnormal embryonic apoptosis in Alx3/Alx4 double mutant mice. Development 128:3975–3986PubMed
21.
González-Rodríguez A, Escribano O, Alba J, Rondinone CM, Benito M, Valverde AM (2007) Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes. J Cell Physiol 212:76–88CrossRefPubMed
22.
Moates JM, Nanda S, Cissell MA, Tsai MJ, Stein R (2003) BETA2 activates transcription from the upstream glucokinase gene promoter in islet β-cells and gut endocrine cells. Diabetes 52:403–408CrossRefPubMed
23.
Artner I, Hang Y, Guo M, Gu G, Stein R (2008) MafA is a dedicated activator of the insulin gene in vivo. J Endocrinol 198:271–279CrossRefPubMed
24.
Andrali SS, Sampley ML, Vanderford NL, Ozcan S (2008) Glucose regulation of insulin gene expression in pancreatic β-cells. Biochem J 415:1–10CrossRefPubMed
25.
Postic C, Shiota M, Magnuson MA (2001) Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 56:195–217CrossRefPubMed
26.
Zelent D, Najafi H, Odili S et al (2005) Glucokinase and glucose homeostasis: proven concepts and new ideas. Biochem Soc Trans 33:306–310CrossRefPubMed
27.
Byrne MM, Sturis J, Clement K et al (1994) Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 93:1120–1130CrossRefPubMed
28.
Pearson ER, Velho G, Clark P et al (2001) β-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations. Diabetes 50:S101–S107CrossRefPubMed
29.
Velho G, Blanch H, Vaxillaire M et al (1997) Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 40:217–224CrossRefPubMed
30.
Terauchi Y, Sakura H, Yasuda K et al (1995) Pancreatic β-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 270:30253–30256CrossRefPubMed
31.
Johnson JD, Ford EL, Bernal-Mizrachi E et al (2006) Suppressed insulin signaling and increased apoptosis in Cd38-null islets. Diabetes 55:2737–2746CrossRefPubMed
32.
Sachdeva MM, Claiborn KC, Khoo C et al (2009) Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress. Proc Natl Acad Sci USA 106:19090–19095CrossRefPubMed
33.
Kim WH, Lee JW, Suh YH et al (2005) Exposure to chronic high glucose induces β-cell apoptosis through decreased interaction of glucokinase with mitochondria. Downregulation of glucokinase in pancreatic β-cells. Diabetes 54:2602–2611CrossRefPubMed
34.
Danial NN, Walensky LD, Zhang CY et al (2008) Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14:144–153CrossRefPubMed
35.
Lakhwani S, Garcia-Sanz P, Vallejo M (2010) Alx3-deficient mice exhibit folic acid-resistant craniofacial midline and neural tube closure defects. Dev Biol 344:869–880CrossRefPubMed
36.
Matveyenko AV, Butler PC (2006) Beta cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes 55:2106–2114CrossRefPubMed
37.
Matveyenko AV, Veldhuis JD, Butler PC (2006) Mechanisms of impaired fasting glucose and glucose intolerance induced by 50% pancreatectomy. Diabetes 55:2347–2356CrossRefPubMed
38.
Kahn SE, Hull RL, Utzschmeider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846CrossRefPubMed
39.
Matveyenko AV, Butler PC (2008) Relationship between β-cell mass and diabetes onset. Diabetes Obes Metab 10:23–31CrossRefPubMed
40.
41.
Holmkvist J, Almgren P, Lyssenko V et al (2008) Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 57:1738–1744CrossRefPubMed
42.
Shih DQ, Heimesaat M, Kuwajima S, Stein R, Wright C, Stoffel M (2002) Profound defects in pancreatic β-cell function in mice with combined heterozygous mutations in Pdx-1, Hnf-1α, and Hnf-3β. Proc Natl Acad Sci USA 99:3818–3823CrossRefPubMed
43.
Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V et al (2005) Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci USA 102:4807–4812CrossRefPubMed
44.
Wallace KJ, Wallis RH, Collins SC et al (2004) Quantitative trait locus dissection in congenic strains of the Goto-Kakizaki rat identifies a region conserved with diabetes loci in human chromosome 1q. Physiol Genomics 19:1–10CrossRefPubMed
45.
Wallis RH, Wang K, Marandi L et al (2009) Type 1 diabetes in the BB rat: a polygenic disease. Diabetes 58:1007–1017CrossRefPubMed
46.
Gao P, Jiao Y, Xiong Q, Wang CY, Gerling I, Gu W (2008) Genetic and molecular basis of QTL of diabetes in mouse: genes and polymorphisms. Curr Genomics 9:324–337CrossRefPubMed
Metadata
Title
Alx3-deficient mice exhibit decreased insulin in beta cells, altered glucose homeostasis and increased apoptosis in pancreatic islets
Authors
M. Mirasierra
A. Fernández-Pérez
N. Díaz-Prieto
M. Vallejo
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1975-6

Other articles of this Issue 2/2011

Diabetologia 2/2011 Go to the issue

For Debate

Targeting energy expenditure via fuel switching and beyond

Article

Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA1c levels in human pancreatic islets

Article

BK channels affect glucose homeostasis and cell viability of murine pancreatic beta cells

Research Letter

Increased fetuin A levels in Helicobacter pylori infection: a missing link between H. pylori and insulin resistance?

Article

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

Research Letter

Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits